Dianthus announces early GO decision in Phase 3 CAPTIVATE CIDP trial; reports FY2025 results

Dianthus Therapeutics, Inc. /DE/

Early GO decision: 20 confirmed responders with less than 40 participants; DSMB confirmed; no serious infections or discontinuations.
Plans to drop 600mg dose arm in Part B; enroll up to 256 patients (down from 480) to randomize 128 (down from 192).
FY2025 net loss $162.3M ($4.20/share) vs $85.0M ($2.55/share) in FY2024.
Cash $514.4M provides runway into 2028.
Phase 3 gMG trial of claseprubart to start mid-2026; top-line data expected 2H’28.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dianthus Therapeutics, Inc. /DE/ reported the fourth quarter and full year ending December 31, 2025 results: net income $162.3 million or $4.20 per share, EPS $4.20 per share.

Period: the fourth quarter and full year ending December 31, 2025
Net income: $162.3 million or $4.20 per share
EPS: $4.20 per share
Result: reported results

Exact text from the filing

On March 9, 2026, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter and full year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

Dianthus Therapeutics, Inc. /DE/ filing history →

Source: SEC EDGAR

accession 0001193125-26-097555

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.